

November 7, 2016
Announcement 1263

Drug Use Review Board (DUR) Approves Changes to MSM Chapter 1200 Effective November 9, 2016

The Nevada Medicaid Drug Use Review (DUR) Board met January 28, 2016, and April 28, 2016, and voted to adopt the following into Medicaid Services Manual (MSM) Chapter 1200 Prescribed Drugs. These changes are effective as of November 9, 2016.

- Updated Criteria:
 - Prior authorization for all medications for recipients over 20 years old who are enrolled in a hospice program (*This change takes effect December 1, 2016*)
 - Medications used to treat Hepatitis C – added criteria for Viekira XR™ and Zepatier™
 - Tasimelteon (Hetlioz®)
 - Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors – added criteria for evolocumab (Repath®)
 - Colchicine
 - Medications used to treat Attention Deficit Hyperactivity Disorder / Attention Deficit Disorder (ADHD/ADD)
 - Naltrexone (Vivitrol®)
 - Colony stimulating factors
 - Medications used for opioid dependence
- New Criteria:
 - Eluxadoline (Viberzi®)
 - Medications used for opioid-induced constipation
 - Neurokinin-1 (NK1) receptor antagonists and combinations
 - Pharmacists to be able to submit prior authorizations